Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase
Articolo
Data di Pubblicazione:
2007
Abstract:
Cyclophosphamide (CYC) is generally considered the most promising agent available today for systemic sclerosis (SSc)-related interstitial lung disease (ILD). However, the optimal dosage and length of treatment are still undetermined. Our objective was to evaluate the effect of an 18-month long protocol with intravenous (iv) CYC.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Adult; Antirheumatic Agents; Carbon Monoxide; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Lung Diseases, Interstitial; Male; Middle Aged; Prospective Studies; Pulse Therapy, Drug; Respiratory Function Tests; Scleroderma, Systemic; Time Factors
Elenco autori:
Airò, P; Danieli, Elisabetta; Rossi, M; Frassi, M; Cavazzana, I; Scarsi, M; Grottolo, A; Franceschini, F; Zambruni, A
Link alla scheda completa:
Pubblicato in: